Timothy A McKinsey

Dr. Timothy A. McKinsey is a Professor in the Department of Medicine at the University of Colorado Denver - Anschutz Medical Campus, where he leads a prominent research program focused on cardiac fibrosis, heart failure, and epigenetic regulation of cardiac disease. His laboratory investigates the molecular mechanisms underlying cardiac remodeling and develops novel therapeutic approaches targeting histone deacetylases and other epigenetic regulators.

Dr. McKinsey's research primarily centers on the role of histone deacetylases (HDACs) in cardiac pathophysiology, with particular emphasis on how epigenetic mechanisms regulate cardiac fibrosis and heart failure. His work spans multiple areas including cardiac fibrosis mechanisms, epigenetic regulation of heart disease, histone deacetylase biology, cardiac remodeling, diastolic dysfunction, and translational approaches to heart failure therapy. His laboratory employs a multidisciplinary approach that combines molecular biology, pharmacology, and advanced cardiac phenotyping to identify novel therapeutic targets for cardiovascular disease.

Analysis of Dr. McKinsey's recent publications reveals a strong focus on the intersection of epigenetics, cardiac fibrosis, and metabolic regulation. His work increasingly incorporates advanced technologies including machine learning approaches to understand cardiac cell behavior, chromatin remodeling in heart failure, and the role of immune cell-fibroblast communication in disease progression. A notable trend is the expansion of his research into adipose tissue-cardiac crosstalk, highlighting the importance of systemic metabolic factors in heart disease.

Dr. McKinsey has secured substantial research funding as Principal Investigator on multiple NIH grants, including several R01 awards from the National Heart, Lung, and Blood Institute. His current projects include "HAT-Dependent Control of Cardiac Fibrosis" (R01HL181226), "15-PGDH-Mediated Eicosanoid Degradation in Cardiac Fibrosis and Heart Failure" (R01HL171711), and "Isoform-Selective HDAC Inhibitors for Age-Associated Diastolic Dysfunction" (R21AG043822), among others. These projects collectively represent millions of dollars in research support focused on understanding and treating cardiac fibrosis and heart failure.

Dr. McKinsey leads a vibrant research team within the Department of Medicine at the University of Colorado Anschutz Medical Campus. His laboratory collaborates extensively with other investigators in cardiology, molecular biology, and translational medicine, contributing to a robust research ecosystem focused on cardiovascular disease mechanisms and therapeutics. His work has positioned him as a leader in the field of cardiac epigenetics and fibrosis research.